# Phenomix Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phenomix-sciences

- Industry: Biotechnology
- Headquarters: Wayzata, US
- Website: https://phenomixsciences.com/
- Total disclosed funding: $5M
- Latest round: Series A (Apr 15, 2024)
- Investors on record: 3

## About

Based in Minnesota, US, and founded in 2021 by co-founders Andres Acosta and Michael Camilleri, Phenomix Sciences, Inc. operates as a medical company providing that develops phenotype-driven multi-mix blood tests to predict weight loss interventions through biological samples, patient assessments, and machine learning. In May 2024, Phenomix Sciences, Inc. received USD 2.3 million in grant funding from Small Business Innovation Research. The round was part of a larger USD 7.3 million Series A and grant funding. 

Phenomix Sciences, Inc. developed a product known as the MyPhenome test, that utilizes biological samples and patient assessments to predict individual responses to various weight loss interventions through machine learning. This test categorizes patients into one of the four obesity phenotypes, allowing healthcare providers to prescribe the most effective treatment plan tailored to the patient's unique needs. The company’s product allows identifies the precise phenotype and ensures that patients receive the right diet, medication, or procedure, doubling the effectiveness of weight loss efforts compared to traditional methods. 

The company plans to use the funding from May 2023 to conduct additional clinical research demonstrating the benefits of obesity precision medicine.

## Funding rounds

- Series A, Apr 15, 2024, $5M — Dexcom, Inc., LabCorp Ventures, Health2047 Capital Partners

## Investors

- Dexcom, Inc. — Series A
- LabCorp Ventures (https://capitalatlas.ai/funds/labcorp-ventures) — Series A
- Health2047 Capital Partners (https://capitalatlas.ai/funds/health2047-capital-partners) — Series A